Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
This study will evaluate the safety and efficacy of a 2.5 mg dose of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) as compared to placebo.
Inclusion Criteria:
Exclusion Criteria:
Laguna Hills, California 92653, United States
San Diego, California 92103, United States
San Diego, California 92120, United States
Tarzana, California 91356, United States
Torrance, California 90505, United States
Denver, Colorado 80220, United States
Englewood, Colorado 80113, United States
Aventura, Florida 33180, United States
Ocala, Florida 34474, United States
Orlando, Florida 32803, United States
Sarasota, Florida 34237, United States
Meridian, Idaho 83642, United States
Annapolis, Maryland 21401, United States
Baltimore, Maryland 21237, United States
Glen Burnie, Maryland 21061, United States
Towson, Maryland 21204, United States
Grand Rapids, Michigan 49546, United States
Sartell, Minnesota 56377, United States
Southaven, Mississippi 38671, United States
Las Vegas, Nevada 89146, United States
Las Vegas, Nevada 89148, United States
Brick, New Jersey 08724, United States
Albuquerque, New Mexico 87109, United States
Albany, New York 12208, United States
Garden City, New York 11530, United States
New York, New York 10016, United States
Bismarck, North Dakota 58501, United States
Oklahoma City, Oklahoma 73104, United States
Bryn Mawr, Pennsylvania 19010, United States
Sewickley, Pennsylvania 15143, United States
Memphis, Tennessee 38119, United States
Houston, Texas 77024, United States
McAllen, Texas 78503, United States
San Antonio, Texas 78229, United States